Immunomodulation as a potent COVID-19 pharmacotherapy: past, present and future

Decsa M. Hertanto MD1,2; Bayu S. Wiratama, MD, MPH, PhD3,4; Henry Sutanto MD, MSc, PhD5,6; Citrawati D.K. Wungu MD, MSi, PhD7,8,*

1Department of Internal Medicine, Faculty of Medicine, Airlangga University, Indonesia
2Department of Internal Medicine, Dr. Soetomo General Hospital, Indonesia
3Department of Epidemiology, Biostatistics, and Population Health, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Indonesia
4Graduate Institute of Injury Prevention and Control, College of Public Health, Taipei Medical University, Taiwan
5Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, The Netherlands
6Department of Physiology and Pharmacology, State University of New York (SUNY) Downstate Health Sciences University, New York, USA
7Department of Physiology and Medical Biochemistry, Faculty of Medicine, Airlangga University, Indonesia
8Institute of Tropical Disease, Airlangga University, Indonesia

Running Title: Immunomodulation in COVID-19

Word Count: 2937 (excluding abstract, references, table and figure legends)

*Correspondence:
Citrawati D. K. Wungu, MD. PhD.
Department of Physiology and Medical Biochemistry, Faculty of Medicine, Airlangga University, Indonesia
Email: citrawati.dyah@fk.unair.ac.id

© 2021 by the author(s). Distributed under a Creative Commons CC BY license.
Abstract
In the first year of its appearance, the 2019 coronavirus disease (COVID-19) has affected more than 150 million individuals and killed 3 million people worldwide. The pandemic has also triggered numerous global initiatives to tackle the newly emerging disease, including the development of SARS-CoV-2 vaccines and the attempt to discover potential pharmacological therapies. Nonetheless, despite the success of SARS-CoV-2 vaccines development, COVID-19 therapy remains challenging. Several repurposed drugs that were documented to be useful in small clinical trials have been shown to be ineffective in larger studies. Additionally, the pathophysiology of SARS-CoV-2 infection displayed the predominance of hyperinflammation and immune dysregulation in inducing multiorgan damage. Therefore, the potential benefits of both immune modulation and suppression in COVID-19 have been extensively discussed. Here, we reviewed the roles of immunomodulation as potential COVID-19 pharmacological modalities based on the existing data and proposed several new immunologic targets to be tested in the foreseeable future.

Keywords: COVID-19; immunomodulation; immunology; immune system; pharmacotherapy; coronavirus; drug repurposing.
Introduction

The 2019 coronavirus disease (COVID-19) is caused by severe acute respiratory syndrome-associated coronavirus type-2 (SARS-CoV-2) infection. In the first year of its appearance, COVID-19 has affected more than 150 million individuals and killed 3 million people worldwide. In some countries, the numbers are still soaring, while in some of the others, the cases are resurging, entering the second and third waves. Such increase could be attributed to several determinants, including the emergence of novel SARS-CoV-2 variants (e.g., N501Y, E484K, B1.1.7), psychological exhaustions (pandemic fatigue) altering the adherence to health protocols, viral reinfection, vaccination delay and the non-existence of potent pharmacological treatments for COVID-19. In most of the contracted patients, COVID-19 is asymptomatic or only causes mild to moderate non-life-threatening symptoms. However, in high-risk individuals, it can cause serious conditions, leading to severe acute respiratory failure, multiorgan dysfunction and death. Therefore, having safe and effective pharmacological agents for COVID-19 is essential to prevent mortality and COVID-19-associated complications (e.g., long COVID).

The recently emerged disease has triggered numerous global initiatives, including the development of SARS-CoV-2 vaccines and the attempt to discover potential pharmacological therapies. Nonetheless, despite the success of SARS-CoV-2 vaccines development, COVID-19 therapy remains challenging. Several repurposed drugs that were documented to be useful in small clinical trials were ineffective in larger studies. For example, the antimalarial drug chloroquine and antimicrobial azithromycin were effective in reducing COVID-19-associated mortality in a non-randomized, retrospective, multicenter study involving 2541 patients.\(^1\) However, in a meta-analysis, the chloroquine and azithromycin-treated group displayed no significant difference in mortality compared to standard care.\(^2\) Moreover, several randomized control trials (RCTs) indicated that chloroquine with/without azithromycin was not effective in improving clinical outcomes\(^3\)\(^-\)\(^5\) or as post-exposure prophylaxis\(^6\). Moreover, those drugs were associated with greater adverse effects, including the occurrence of malignant arrhythmias.\(^7\) Similarly, the use of human immunodeficiency virus protease inhibitors ritonavir/lopinavir was no longer recommended following studies reporting no benefit compared to standard care.\(^8\),\(^9\) Meanwhile, for months, no large RCTs reported the benefits of antiparasitic ivermectin
and antiviral favipiravir in COVID-19, although some small studies reported conflicting results for ivermectin\textsuperscript{10, 11} and favipiravir\textsuperscript{12, 13}. For example, in an RCT involving 400 adult patients with mild COVID-19, no clinical improvement was observed in patient receiving ivermectin compared to placebo.\textsuperscript{10} To date, only antiviral remdesivir was shown to facilitate significant clinical improvements and has been authorized for COVID-19 by major drug safety regulators.\textsuperscript{14, 15}

Likewise, the pathophysiology and key determinants of the disease have not been fully elucidated. Several data pointed toward the strong involvement of proinflammatory mediators (Figure 1), with evidences of cytokine release syndrome (i.e., life-threatening systemic hyperinflammation and immune dysregulation) which are essential to induce multiorgan dysfunction and failure, worsening the prognosis of COVID-19.\textsuperscript{16, 17} Therefore, immunosuppression could potentially be beneficial in the COVID-19 management.\textsuperscript{18} However, previous systematic review reported that immunocompromised patients with COVID-19 had higher comorbidities, rates of intensive care and hospital mortality\textsuperscript{19}, indicating the potential risk of immunosuppression in COVID-19. Thus, in this narrative review, we explore the documented effects of immunosuppressive medications (e.g., corticosteroids, interleukin (IL)-1 inhibitors, IL-6 inhibitors and kinase inhibitors) and immunomodulators (e.g., interferon alpha (IFNα), interferon beta (IFNβ), non-SARS-CoV-2 specific immunoglobulin and convalescent plasma) in COVID-19 (Table 1) and propose some potential immunologic targets to test in the foreseeable future.

### Table 1. A summary of landmark RCTs reporting the effects of immunomodulation in COVID-19 management

<table>
<thead>
<tr>
<th>Investigators</th>
<th>Sample size and characteristics</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Corticosteroids</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RECOVERY</td>
<td>2104 hospitalized COVID-19</td>
<td>Dexamethasone lowered 28-day mortality in patients receiving either invasive mechanical ventilation or oxygen alone at randomization, but not among those without respiratory support.</td>
</tr>
<tr>
<td>(dexamethasone)</td>
<td>patients receiving dexamethasone and 4321 patients with usual care</td>
<td></td>
</tr>
<tr>
<td>Horby et al.\textsuperscript{22}</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CoDEX</td>
<td>299 COVID-19 patients with moderate/severe ARDS were randomized (151 received dexamethasone with standard</td>
<td>Dexamethasone plus standard care compared with standard care alone increased the number of ventilator-free</td>
</tr>
<tr>
<td>Tomazini et al.\textsuperscript{25}</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Patients</td>
<td>Intervention</td>
</tr>
<tr>
<td>--------------------------</td>
<td>----------</td>
<td>--------------</td>
</tr>
<tr>
<td><strong>REMAP-CAP</strong>&lt;sup&gt;27&lt;/sup&gt;</td>
<td>403</td>
<td>7-day fixed-dose hydrocortisone or shock-dependent hydrocortisone</td>
</tr>
<tr>
<td><strong>CAPE COVID</strong>&lt;sup&gt;26&lt;/sup&gt;</td>
<td>149</td>
<td>Low-dose hydrocortisone, compared with placebo, did not significantly reduce death or persistent respiratory support at day 21 in critically ill patients with SARS-CoV-2 infection and acute respiratory failure.</td>
</tr>
<tr>
<td><strong>Interleukin inhibitors</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>REMAP-CAP</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gordon et al.&lt;sup&gt;32&lt;/sup&gt;</td>
<td>353</td>
<td>48 to sarilumab, and 402 to control.</td>
</tr>
<tr>
<td><strong>RECOVERY (tocilizumab)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abani et al.&lt;sup&gt;33&lt;/sup&gt;</td>
<td>Hospitalized COVID-19 patients with hypoxia and systemic inflammation were randomly allocated to tocilizumab (n = 2022) and to usual care (n = 2094).</td>
<td>Tocilizumab improved survival and other clinical outcomes in hospitalized COVID-19 patients with hypoxia and systemic inflammation.</td>
</tr>
<tr>
<td><strong>COVACTA</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rosas et al.&lt;sup&gt;36&lt;/sup&gt;</td>
<td>438</td>
<td></td>
</tr>
<tr>
<td><strong>Boston Area COVID-19 Consortium (BACC) Bay Tocilizumab Trial</strong>&lt;sup&gt;37&lt;/sup&gt;</td>
<td>243</td>
<td></td>
</tr>
<tr>
<td><strong>EMPACTA</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salama et al.&lt;sup&gt;38&lt;/sup&gt;</td>
<td>389</td>
<td></td>
</tr>
</tbody>
</table>

**Kinase inhibitors**

<table>
<thead>
<tr>
<th>Study</th>
<th>Patients</th>
<th>Intervention</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>RECOVERY</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abani et al.&lt;sup&gt;33&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Boston Area COVID-19 Consortium (BACC) Bay Tocilizumab Trial&lt;sup&gt;37&lt;/sup&gt;</td>
<td>243</td>
<td></td>
<td>Tocilizumab was not effective for preventing intubation or death in moderately-ill hospitalized patients with COVID-19.</td>
</tr>
<tr>
<td><strong>EMPACTA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salama et al.&lt;sup&gt;38&lt;/sup&gt;</td>
<td>389</td>
<td></td>
<td>Tocilizumab reduced the likelihood of progression to the composite outcome of mechanical ventilation or death, but it did not improve survival in hospitalized patients with COVID-19 pneumonia who were not receiving mechanical ventilation.</td>
</tr>
<tr>
<td>Study</td>
<td>Intervention</td>
<td>Findings</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>--------------</td>
<td>----------</td>
<td></td>
</tr>
<tr>
<td><strong>ACTT-1</strong>&lt;br&gt;(baricitinib/remdesivir)&lt;br&gt;Kaliil et al.42</td>
<td>1033 hospitalized COVID-19 patients underwent randomization (with 515 assigned to combination treatment and 518 to remdesivir alone)</td>
<td>Baricitinib/remdesivir was superior than remdesivir alone in facilitating recovery and accelerating improvement in clinical status among COVID-19 patients, especially with high-flow oxygen or noninvasive ventilation. The combination was also associated with fewer major adverse events.</td>
<td></td>
</tr>
<tr>
<td><strong>Interferons</strong></td>
<td>42 severe COVID-19 patients received IFN β-1a in addition to the national protocol medications (hydroxychloroquine plus lopinavir-ritonavir or atazanavir-ritonavir) and 39 patients received only the national protocol medications (control)</td>
<td>IFN significantly increased discharge rate at day 14 and decreased 28-day mortality in severe COVID-19 patients but did not change the time to reach the clinical response.</td>
<td></td>
</tr>
<tr>
<td><strong>WHO SOLIDARITY</strong>&lt;br&gt;Pan et al.46</td>
<td>11330 hospitalized COVID-19 adults underwent randomization; 2750 received remdesivir, 954 with hydroxychloroquine, 1411 with lopinavir (without IFN), 2063 with IFN (including 651 IFN plus lopinavir), and 4088 with no trial drug</td>
<td>IFN had no effect on hospitalized patients with COVID-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay.</td>
<td></td>
</tr>
<tr>
<td><strong>Hyperimmune globulin and convalescent plasma</strong></td>
<td>Of 11558 hospitalized COVID-19 patients, 5795 were randomly assigned to the convalescent plasma and 5763 to the usual care groups</td>
<td>High-titer convalescent plasma did not improve survival or other pre-specified clinical outcomes in hospitalized COVID-19 patients.</td>
<td></td>
</tr>
<tr>
<td><strong>RECOVERY</strong>&lt;br&gt;(convalescent plasma)&lt;br&gt;Abani et al.51</td>
<td>464 moderate COVID-19 adults (235 with convalescent plasma and best standard of care and 229 with best standard of care only)</td>
<td>Convalescent plasma was not associated with a reduction in progression to severe COVID-19 or all-cause mortality.</td>
<td></td>
</tr>
<tr>
<td><strong>PLACID</strong>&lt;br&gt;Agarwal et al.52</td>
<td>Hospitalized adult patients with severe COVID-19 pneumonia (228 received convalescent plasma and 105 received placebo)</td>
<td>No significant differences were observed in clinical status or overall mortality between patients treated with convalescent plasma and those who received placebo.</td>
<td></td>
</tr>
<tr>
<td><strong>PlasmAr</strong>&lt;br&gt;Simonovich et al.53</td>
<td>Severe COVID-19 patients who did not respond to initial treatments (30 received IVIg and 29 patients received placebo)</td>
<td>IVIg improved clinical outcome and significantly reduced mortality rate in severe COVID-19 patients who did not respond to initial treatment.</td>
<td></td>
</tr>
</tbody>
</table>
Figure 1. The entry process of SARS-CoV-2 into alveolar epithelial cells, immune response activation and druggable immunologic targets in COVID-19. The SARS-CoV-2 enters the infected person via the respiratory tract and attaches to the ACE2 receptors in type-2 alveolar cells of the lungs. It subsequently activates the retinoic acid inducible gene-(RIG) I-like receptors (RLRs), which play an essential role in the activation of antiviral immune responses. Together with the intrinsic response to the viral particles, they induce hyperactive inflammatory response, marked by the activation of proinflammatory cytokines-releasing cells. Several immunologic targets were identified to have an important role in the COVID-19-mediated immune dysregulation, therefore some pharmacological agents are repurposed to reduce the COVID-19-induced hyperinflammation and to prevent the viral entry and replications. (ACE2 = angiotensin converting enzyme type-2; CoV = coronavirus; IL = interleukin; SARS = severe acute respiratory syndrome; NK = natural killer; TNF = tumour necrosis factor)

Immunosuppression in COVID-19

Hyperactivation of immune system is a hallmark of COVID-19 severity. Ample evidences have reported higher number of leukocytes, increased levels of procalcitonin, C-reactive
protein (CRP), and other proinflammatory cytokines (e.g., IL-1 and IL-6) / chemokines (e.g., CXCL10 and CCL2) in COVID-19 patients requiring intensive care. Such hyperactive inflammatory response initiates cytokine release syndrome and may contribute to the uncontrolled apoptosis, vascular leakage, thromboembolism, multiorgan damage and death. Therefore, immunosuppression has been proposed as a potential therapeutic strategy in COVID-19.

Corticosteroids have a potent anti-inflammatory effect and are currently being used to treat dysregulated inflammatory response in autoimmune diseases. In COVID-19, inhaled corticosteroid ciclesonide inhibited SARS-CoV-2 ribonucleic acid (RNA) replication by targeting viral replication-transcription complex. Despite the failure of corticosteroids to show significant benefits and their association with delayed viral clearance in previous coronavirus (SARS-CoV-1 and MERS-CoV) diseases, studies investigating the effects of corticosteroids in COVID-19 showed several promising results. For example, methylprednisolone lowered COVID-19-associated mortality in patients with acute respiratory distress syndrome and reduced the duration of supplemental oxygen in COVID-19 patients. More recently, Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial, a randomized controlled open-label trial, reported that dexamethasone lowered the 28-day mortality among patients receiving invasive mechanical ventilation (RR 0.65; [95% CI = 0.48-0.88]; p=0.0003) and among those receiving oxygen without invasive mechanical ventilation (0.80; [0.67-0.96]; p=0.0021), but not among those who received no respiratory support (1.22; [0.86 to 1.75]; p=0.14). The study was performed on 2104 patients who were randomized and given dexamethasone 6 mg once daily for ten days, either orally or by intravenous injection, and compared with 4321 patients receiving standard therapy. The study also showed that dexamethasone lowered 28-day mortality by 17% (0.83; [0.74-0.92]; P=0.0007).

Consistently, a meta-analysis of 7 RCTs, such as the ongoing DEXA-COVID19, ongoing COVID STEROID, CoDEX, CoEX, CAPE COVID, REMAP-CAP and unpublished Steroids-SARI, concluded that corticosteroids compared with usual care or placebo lowered the 28-day all-cause mortality. However, in adults with non-severe COVID-19, corticosteroids therapy was associated with worse clinical outcomes, a higher risk of progression of severity and prolonged hospital stay, highlighting the
potential benefits of corticosteroids in the treatment of moderate/severe COVID-19 patients. Additionally, a recent retrospective study reported that delayed SARS-CoV-2 clearance observed in moderate/severe COVID-19 was not associated with an early use of corticosteroids.³⁰

Interleukin inhibitors are commonly prescribed in autoimmune diseases and other hyperinflammatory states. Several interleukins are responsible for COVID-19-mediated cytokine releases (e.g., IL-1β, IL-6 and IL-18) and their inhibition could be beneficial. A cohort of 117 patients with respiratory insufficiency and hyperinflammation receiving either IL-1 or IL-6 inhibitors reported that IL-1 inhibition (with anakinra) significantly reduced mortality in COVID-19 patients with respiratory insufficiency and hyperinflammation. Meanwhile, IL-6 inhibition (with tocilizumab or sarilumab) was only effective in a subgroup of patients with high CRP or low lactate dehydrogenase.³¹

Additionally, in the Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAPCAP), IL-6 inhibitors also improved survivals in critically ill COVID-19 patients receiving intensive organ support.³² The RECOVERY trial, a large randomized, controlled, open-label, platform trial which enrolled 4116 patients reported that tocilizumab could increase the probability of patients discharged alive from hospital within 28 days (57% vs 50%; 1.22; 95% CI = 1.12–1.33; p<0.0001). Tocilizumab also reduced the 28-days mortality in severe COVID-19 patients as compared to standard therapy alone (0.86; 95% CI = 0.77-0.96; p=0.007).³³ Moreover, in a meta-analysis of 71 (heterogenous) studies, tocilizumab was consistently associated with a lower relative risk of mortality in prospective studies, but effects were inconclusive for other outcomes.³⁴ Another meta-analysis involving large-scale studies showed that tocilizumab may have substantial effectiveness in reducing mortality among COVID-19 patients, especially among critical cases;³⁵ underlining the prospective benefits of IL inhibition in COVID-19. Nevertheless, in the COVACTA trial, an RCT involving 452 hospitalized patients with severe COVID-19-associated pneumonia, the use of tocilizumab did not significantly improve clinical status or lower mortality than placebo at 28 days.³⁶ Another randomized double blind, placebo-controlled trial (Boston Area COVID-19 Consortium Bay Tocilizumab Trial) showed that tocilizumab was not effective in preventing intubation or mortality in moderately ill hospitalized COVID-19 patients.³⁷
Meanwhile, the EMPACTA (Evaluating Minority Patients with Actemra) study, a global, phase 3 clinical trial, reported that in 249 hospitalized patients with COVID-19-associated pneumonia without mechanical ventilation, tocilizumab did not improve survival, although it reduced the likelihood of progression to the composite outcome of mechanical ventilation or death. These studies suggested that tocilizumab may exhibit different clinical outcome depending on the severity of COVID-19 and the need for mechanical ventilation.

Kinase inhibitors inhibit numerous kinases that are important for viral infection (e.g., ABL, numb-associated kinase, cyclin dependent kinase, phosphoinositide 3 kinase/protein kinase B/mechanistic target of rapamycin [mTOR], extracellular signal-regulated kinase/mitogen-activated protein kinase and janus kinase [JAK]) and predicted to be involved in mediating infection by SARS-CoV-2. They play important roles in viral entry, intracellular membrane trafficking, viral replication and viral life cycle, and possess an immunomodulatory effect that could be useful against COVID-19-mediated hyperactive immune response. However, a recent in-vitro study showed that imatinib, an ABL inhibitor, did not inhibit SARS-CoV-2 entry/infection and replication. Meanwhile, baricitinib, a JAK inhibitor, prevented phosphorylation of key proteins involved in the signal transduction that leads to immune activation and inflammation (e.g., the cellular response to IL-6). In a double-blind, randomized, placebo-controlled trial of 1033 patients, baricitinib/remdesivir was superior to remdesivir alone in reducing recovery time and accelerating clinical improvement, and associated with fewer serious adverse events in COVID-19 patients receiving high-flow oxygen or non-invasive ventilation.

**Immune system modulation in COVID-19**

In addition to immunosuppression, several immunomodulators are proposed in COVID-19 management and expected to restore the immunologic homeostasis in COVID-19 patients. Interferons are cytokines—made and released by host cells in response to viral pathogens. SARS-CoV-2 could escape innate immunity early during the infection by altering intrinsic IFN effect in limiting viral replication and spread. In a retrospective cohort of 77 adults
with moderate COVID-19, treatments using nebulized IFNα-2b yielded a shorter time to viral clearance from the upper respiratory tract and a reduction in systemic inflammation.\textsuperscript{44} In a randomized controlled trial of 42 patients receiving subcutaneous IFNβ-1a on top of hydroxychloroquine/lopinavir/ritonavir or atazanavir/ritonavir therapies, IFNβ-1a significantly increased discharge rate at day-14 and reduced 28-day mortality.\textsuperscript{45} However, the interim results of the World Health Organization (WHO) Solidarity trial displayed no difference in mortality rate between patients administered with IFNβ-1a and standard care (1.16; 95% CI = 0.96-1.39; P=0.11).\textsuperscript{46} More data investigating the effects of IFN are required due to an increasing evidence that patients with severe COVID-19 have a robust type-I IFN response, in contrasts with the delayed, possibly suppressed, IFN response in the early phase of SARS-CoV-2 infection.\textsuperscript{47}

Hyperimmune globulin and convalescent plasma are derived from individuals with high antibody titers to specific pathogens and can provide passive immunity (i.e., neutralizing antibodies) against particular infectious agents. It was effective in treating SARS-CoV-1 and MERS-CoV infections by increasing the discharge rate and lowering mortality.\textsuperscript{48} In a retrospective, propensity score-matched case-control study in 39 patients with severe or life-threatening COVID-19, convalescent plasma reduced the oxygen requirements at day-14 after transfusion and improved survivals.\textsuperscript{49} Another retrospective multicenter observational study also showed that patients who had an early initiation of plasma therapy displayed a shorter duration of hospitalization (12.7 vs 24.3 days, p = 0.000).\textsuperscript{50} Interestingly, such observation was not documented in RCTs, including the RECOVERY trial, in which high-titer convalescent plasma did not improve survival or other pre-specified clinical outcomes.\textsuperscript{51} A meta-analysis of 10 RCTs, including PLACID\textsuperscript{52} and PlasmAr\textsuperscript{53} trials also reported that the treatment with convalescent plasma compared to placebo or standard care was not significantly associated with a decrease in all-cause mortality or with any benefit for other clinical outcomes.\textsuperscript{54} Since the majority of the RCTs also involved moderate to severe COVID-19 patients, this finding discrepancy might not be due to the difference on disease severity. Nonetheless, convalescent plasma may still be an alternative in COVID-19 patients with specific comorbidities. For example, in a cohort study, an early administration of convalescent plasma improved survival in COVID-19 patients with hematological malignancies.\textsuperscript{55} Additionally, in a nationwide observational
multicenter study, the administration of convalescent plasma improved clinical outcomes in B-cell–depleted patients with protracted COVID-19.\textsuperscript{56} Overall, these data suggested that application of convalescent plasma in COVID-19 might be limited.

Non-SARS-CoV-2 specific intravenous immunoglobulin (IVIg) is a product derived from the pooled plasma of donors that provides passive immunity against a broad range of pathogens and commonly used for treatment of primary and secondary immunodeficiencies, autoimmune/inflammatory conditions, neuro-immunologic disorders, and infection-related sequelae.\textsuperscript{48} In autoimmune diseases, IVIg modulates the activation and effector functions of B and T lymphocytes, neutralizes pathogenic autoantibodies, interferes with antigen presentation and therefore, has a strong anti-inflammatory effect.\textsuperscript{57} In COVID-19, although the exact mechanism of action is unclear, it is hypothesized that IVIg exerts its beneficial effect through the modulation of inflammation, including the presence of anti-idiotypic antibodies and IgG dimers blocking the FcγR activation on innate immune effector cells,\textsuperscript{48} complement scavenging, and reciprocal regulation of effector Th1, Th17 and regulatory T-cells. Moreover, IVIg also decreased plasma IL-6 and CRP levels.\textsuperscript{58} A double-blind randomized placebo-controlled trial involving 59 patients with severe COVID-19 who did not respond to initial treatments reported an improvement of clinical outcome and a reduction in mortality following the administration of IVIg.\textsuperscript{59} Similarly, several retrospective studies also reported the benefits of early IVIg in reducing the 28-day and 60-day mortality, hospital stay, inflammatory response, and improving multiorgan physiology and clinical outcome of severe COVID-19 patients,\textsuperscript{58} which effects are more prominent in those having no comorbidities or being treated at an earlier stage.\textsuperscript{60}

**Phase identification is the key to a prompt immune modulation**

The majority of previous clinical trials indicated that both immunosuppression and immunomodulation were effective in severe/critical COVID-19 conditions requiring respiratory support and ventilation, while in non-severe disease, immunologic treatments might elicit worse outcome (e.g., corticosteroid) or no significant improvements of clinical outcome or mortality (Table 1). WHO guideline also strongly recommends systemic corticosteroid administration (i.e. dexamethasone, hydrocortisone or prednisone) in patients with severe and critical COVID-19 either orally or intravenously, while in non-
severe COVID-19 patients, WHO advises against the use of corticosteroids unless the patient is already taking this medication for pre-existing conditions. This fits well with the identified disease pathophysiology (Figure 2) implying the hyperinflammatory state with cytokine release syndrome in severe COVID-19. In such conditions, inhibition of proinflammatory cytokines with immunosuppressive agents could reduce the damaging consequences of rogue inflammation and immunomodulation might restore the host immune regulation. On the other hand, in the early phase, immunologic treatments tend to disrupt the activation of immune response against viruses and therefore, could be detrimental. Tailoring treatments in line with the phase of COVID-19 disease course is critically important and supported by data from major clinical trials. For example, in the Adaptive COVID-19 Treatment Trial (ACTT-1), remdesivir was shown to work best in the early phase of the disease, while the RECOVERY trial indicated that dexamethasone was best administered in the late phase. Nonetheless, the roles of immune system modulation in COVID-19 caused by recently emerged SARS-CoV-2 variants (B1.1.7, B.1.1.7/E484K, B.1.351 and P.1) remain unknown. Those variants resulted in a higher mortality than the original SARS-CoV-2 and could possess distinct responses to immune-based therapy, although further research are warranted.
Figure 2. The phases of COVID-19. The COVID-19 can be divided into 3 stadiums: the early infection, the pulmonary and the hyperinflammation stages. In the early infection, the viral load (purple line in the blue zone) starts to increase and at some points, it begins to activate the host immune response (red zone). While the disease progresses into a more severe state, the proinflammatory cytokines build up and start to form antibody against the virus. When the disease is not promptly treated, COVID-19 may fall into the hyperinflammation stage, multiorgan failure and death. (ARDS = acute respiratory distress syndrome; MODS = multiorgan dysfunction syndrome)

Future immunologic targets for COVID-19

In the future, several novel immunologic targets, such as tumor necrosis factor (TNF)-α inhibitors, retinoic acid inducible gene I-like receptor (RLR) and mTOR inhibitors, NLRP3 inflammasome inhibitors, complement inhibitors, toll-like receptor modulators, IL-18 inhibitors and possibly mesenchymal stem-cell secretome may be tested due to their reported significance in COVID-19 pathogenesis.
A few studies have shown that TNF-α inhibition reduced mortality and hospital admission in COVID-19 patients. In a group of patients with inflammatory bowel disease and COVID-19, TNF-α inhibition was inversely associated with the composite outcome of death or hospital admission for COVID-19. Moreover, among others, data from 600 rheumatic patients with COVID-19 showed that TNF-α inhibitor, either alone or in combination with other immunomodulatory drugs, was associated with a lower rate of hospital admission for COVID-19. However, those studies were conducted in patients with immunologic disorders who perhaps already developed chronic immune system remodeling, thus might provide distinct immune response against SARS-CoV-2 infection. Hence, further clinical study on the efficacy of TNF-α inhibitors in COVID-19 patients without immune-related comorbidities is warranted.

Complement system inhibition is also a potential therapeutic target for COVID-19. A preliminary data by Gao et al. (2020) demonstrated the presence of complement hyperactivation (e.g., widespread C3 and C5 complements deposition) in COVID-19 and the activation, either through classical or alternative routes, can contribute to the maladaptive inflammatory response, escalating the infection severity. Therefore, several clinical trials have been initiated to investigate the potential role of complement inhibitors in COVID-19. For example, the combination of C5 inhibitor ravulizumab and JAK inhibitor baricitinib, which is now entering the phase IV clinical trial.

Meanwhile, RLR is activated following the identification of viral RNAs in the cytoplasm of infected cells, initiating the production of type I and III IFNs and inflammatory cytokines. Therefore, the inhibition of RLR could alter the interactions between host and viral factors, which potentially prevent the activation of excessive inflammatory response in COVID-19. Previous studies also reported the activation of NLRP3 inflammasome in COVID-19, which facilitates the initiation of major proinflammatory cytokines, such as IL-1β and IL-18. Therefore, inhibitions of NLRP3 inflammasome and its downstream mediators (e.g., IL-1β and IL-18) could potentially reduce COVID-19-associated morbidity and mortality by minimizing the hyperinflammatory state. Lastly, although is still in the early phase, the possible contributions of mesenchymal stem cells and their secretome in COVID-19 management are being investigated. Nonetheless, at present, those potential targets...
remain at the investigational stage and further extensive experimental and clinical studies are required to evaluate their effectivity in COVID-19.

**Conclusions**

Both immunosuppression and immunomodulation could serve as potent COVID-19 pharmacotherapies when they are administered in an appropriate disease stage / severity (Figure 2). Patients' characteristics and comorbidities have to be considered to minimize adverse effects and complications of immunotherapies. At present, several new pharmacological targets are being investigated and in the near future, they are expected to contribute to the COVID-19 management.

**Funding**

None

**Author contribution**

All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work.

**Conflict of interest**

None
REFERENCES


Bowel Diseases: Results From an International Registry. *Gastroenterology* 2020;**159**:481-491 e483.


